Drug intelligence / Profile preview

dicyclomine

Development stage
Approved
Lead developer
Allergan
Modality
Small Molecules
Administration
Oral, Intramuscular
01

Overview

Dicyclomine (also known as dicycloverine) is an anticholinergic and antispasmodic small molecule drug primarily used to treat symptoms of irritable bowel syndrome (IBS), particularly intestinal spasms and hypermotility. It acts as a muscarinic receptor antagonist—specifically at the M1, M2, and M3 subtypes—blocking acetylcholine at these sites in the gastrointestinal tract. This leads to relaxation of smooth muscle and reduced cramping. Dicyclomine also non-competitively inhibits bradykinin- and histamine-induced spasms in the gut. The drug was first approved for medical use in 1950 and is available both as a generic medication and under several brand names[1][2][4][5][6][7].

Brand names
BentylDibentDicyclocot
Other names
dicycloverine
02

Targets

M1 (Muscarinic acetylcholine receptor M1)HRH1 (Histamine H1 Receptor)CHRM3 (M3)CHRM2 (M2)

Beyond the preview

Go deeper on dicyclomine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dicyclomine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call